Stocks
G1 Therapeutics IncGTHX
HealthcareBiotechnology
A biopharmaceutical company focused on developing and commercializing therapies for cancer, with its lead product, trilaciclib, designed to protect bone marrow during chemotherapy. The company's commercial-stage status and pipeline progress make it a stock of interest for investors tracking oncology innovation and small-cap biotech volatility.
Congressional Interest in G1 Therapeutics Inc (GTHX)
1 member of Congress has disclosed 1 trade in G1 Therapeutics Inc (GTHX), a Healthcare company. The buy/sell breakdown shows 1 purchase versus 0 sales, indicating net buying interest from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
1
Unique Politicians
1
Buys
1
Sells
0
Who in Congress Is Trading GTHX?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2023-06-29 | Rohit Khanna | buy | $1K-$15K |